key: cord-0686615-s25hvhwh authors: Torre, Alessandro; Aliberti, Stefano; Castellotti, Paola; Cirillo, Daniela Maria; Grisolia, Antonella; Mangioni, Davide; Marchetti, Giulia; Rossotti, Roberto; Santus, Pierachille; Besozzi, Giorgio; Villa, Simone; Codecasa, Luigi Ruffo title: Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy date: 2020-11-06 journal: Respir Med DOI: 10.1016/j.rmed.2020.106204 sha: 8fc5cc1ffdacb617ad05ea247c1e613a18ec10cb doc_id: 686615 cord_uid: s25hvhwh COVID-19, the novel coronavirus pandemic, has already spread around the globe affecting more than 18 million people. As previously observed with other coronaviruses, SARS-CoV-2 deeply dysregulate the immune system eliciting respiratory failure and a state of systemic hyperinflammation in severely ill individuals. Immunotherapy is often used to downgrade the detrimental effects of the disease sustained by high-level of cytokines. Those treatments, however, are known to undermine patients’ ability to contain tuberculosis (TB) infection. This study aims to describe interferon-γ release assay (IGRA) results in severe COVID-19 patients eligible for immunosuppressive treatment. Aggregate data were gathered from five hospitals in Milan, Italy, from March 1 to May 15, 2020 and retrospectively analyses. Results were summarized using absolute frequencies and percentages and compared using a two-sided Chi-squared test. Overall, 462 COVID-19 patients were eligible for immunosuppressive therapy, among which 335 were tested using IGRA testing. More than one-third of them (122/335; 36.4%) had an indeterminate IGRA result because of insufficient immune response to mitogen control, 19 (5.7%) tested positive and 194 (57.9) negative. The majority of patients with lymphocytopenia (i.e., total lymphocyte count [TLC] below 1000 cells/mm(3)) had indeterminate IGRAs (81/155; 52.3%). The proportion becomes even higher in patients with severe lymphocytopenia (i.e., TLC<500 cells/mm(3)) (36/57; 63%). Our results suggest a possible negative impact of COVID-19 related immune dysregulation on TB infection assessment and management. Close monitoring of individuals with or without retesting of individuals with indeterminate IGRAs and further basic science investigations should to be sought to better comprehend their implication on TB epidemiology. contained by a persistent host immune response-through tuberculin skin test (TST) or interferonγ release assay (IGRA). 4 However, a severe state of SARS-CoV-2 infection and the concurrent administration of immunosuppressive agents might play a role in making TBI progress into disease 5, 6 and ultimately worsen its outcome, because of the lung damage produced by COVID-19. [7] [8] [9] In general, IGRA testing may results indeterminate in 2-11% of cases, particularly in subjects with chronic conditions such as rheumatologic or immunosuppressive states. 10 Furthermore, a low lymphocyte count is a well-known potential cause of false-negative TST and/or indeterminate IGRA results, the latter due to an insufficient immune response to the mitogen control. 11, 12 Many Italian COVID-19 Units included IGRA testing in the panel of preliminary exams to prescribe anti-inflammatory treatments. Given the necessity for the quickest start of therapy to contrast COVID-19-related massive cytokines release, the usual laboratory turn-around time for response (on average, 3-7 days) was considered not compatible with clinical urgency. Considering the short treatment course of cytokine-blocking agents in COVID-19 (1-2 doses for tocilizumab; 2 weeks or less for high-dose anakinra) and the relatively brief duration of the iatrogenic immunosuppression (4 weeks after drug administration for tocilizumab; until drug discontinuation for anakinra), some COVID-19 Units seldom wait for IGRA results before starting these therapies, while others simply do not include TBI screening as a pre-requisite. Aim of this retrospective study was to describe the IGRA testing results among severe COVID-19 patients eligible for immunosuppressive treatment. We retrospectively assessed the results of IGRA testing performed in patients with severe COVID-19 admitted in five hospitals of the Milan area by collecting and analysing aggregate data with no access to patients' medical records; therefore, no ethical clearance was required. All the centres employed QuantiFERON-TB Gold Plus® (QTP) (DiaSorin; Salluggia, Italy) as IGRA testing before starting immunosuppressive treatment, according to local protocols. Results of IGRA testing were assessed according to manufacturer's criteria. Screening policies differed widely according to local decision processes, ranging from testing all possible candidates to not testing any of them. Data were summarized using absolute frequencies and percentages and comparison between groups, defined by IGRA results, and compared using a two-sided Pearson's Chi-squared test using R software (version 3.6.3). Overall , TPT was administered only in two patients with a positive IGRA result. This data support the role of severe damage of the immune response secondary to COVID-19 underlying the possible threatening consequences about TB epidemiology after the pandemic. 13 Indeed, it is unclear how an indeterminate IGRA result should be interpreted when registered in patients with acute viral infections 14 . Yet, it is disputed how to manage these patients especially as the need of a TPT after only few doses of immune suppressive treatment is not well documented 15 . Additionally, age and possible co-morbidities may discourage treatment start and hinder its completion because the development of undesirable adverse events. An indeterminate IGRA result in these anergic patients, with no data on the influence of COVID-19 on the TBI progression, may delay eventually TB diagnosis and care leading to poor outcome. 16, 17 For all these reasons, we propose a follow-up period of at least two years with periodic (i.e., at month 2, 6, 12, and 24 after the first test) clinical, immunological (with IGRA testing), and radiological reassessment to those resulted indeterminate as displayed in Figure 1 . This reassessment may be supported by previous study suggesting a change in IGRA result after months from the indeterminate result. 10 Being a retrospective analysis of aggregated data, many confounders may have been overlooked, including the presence of chronic rheumatologic or systemic diseases or acute conditions known to affect IGRA results. 10 Nevertheless, we believe that COVID-19-driven immune disturbance (both quantitative and qualitative) plays a major role due the high number of indeterminate IGRA testing. As countries with high rate of TB are the ones most at risk to struggle for COVID-19, prospective controlled studies are urgently needed to confirm our results and their clinical implication. 15 Also, an international consensus should be agreed on how to manage individuals with positive or indeterminate IGRA affected by COVID-19 to avoid surge in TB cases. J o u r n a l P r e -p r o o f * A high TB incidence country has been defined as a TB incidence > 50 per 100,000 based on WHO estimates. 4 † P-value is computed using Pearson's Chi-squared test in R version 3.6.3 applying a significance level of 95% in a two-sided distribution. Abbreviations: IGRA, interferon-γ release assay; TB, tuberculosis; TLC, total lymphocyte count; WHO, World Health Writing -review & editing; Stefano Aliberti: Conceptualization, Data curation, Investigation, Methodology, Writing -review & editing; Paola Castellotti: Data curation, Investigation, Writing -original draft Cirillo: Conceptualization, Investigation, Methodology, Supervision, Writing -review & editing Writing -review & editing Davide Mangioni: Conceptualization, Data curation, Investigation, Writing -review & editing Writing -review & editing; Roberto Rossotti: Data curation, Investigation, Writing -review & editing; Pierachille Santus: Data curation, Methodology, Investigation, Writing -review & editing; Giorgio Besozzi: Data curation, Investigation, Supervision, Validation Formal analysis, Visualization, Writingreview & editing Codecasa: Conceptualization, Data curation, Investigation, Methodology, Project administration, Supervision, Writing -original draft, Writing -review & editing COVID-19 study group Investigators: Stefano Aliberti The Milan TB-COVID-19 study group Participating Centers: • Infectious Disease Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Granda Ospedale Maggiore Policlinico • 3 rd Division, Department of Infectious Diseases • Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico • Clinic of Infectious and Tropical Diseases, Department of Health Sciences • Division of Respiratory Diseases World Health Organization. WHO Health Emergency Dashboard Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia Dysregulation of Immune Response in Patients With Coronavirus On tuberculosis and COVID-19 co-infection Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts Abnormal pulmonary function in COVID-19 patients at time of hospital discharge Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results Use of T-SPOT.TB in latent tuberculosis infection diagnosis in general and immunosuppressed populations Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study The Potential Impact of the Covid-19 Response on Tuberculosis in High-Burden Countries: a Modelling Analysis Epidemic and pandemic viral infections: impact on tuberculosis and the lung. A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN) and members # of ESCMID Study Group for Mycob Tuberculosis sepsis after tocilizumab treatment IFN-γ Release Assay Result Is Associated with Disease Site and Death in Active Tuberculosis Concurrent cavitary pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy: a case report